FDMT: 4dmoleculartherapeutics.com Debt to Equity

This daily price chart for 4D Molecular Therapeutics (FDMT) on the GURU.Markets platform, where the debt-to-equity ratio stands at 0.10, reflects the business's dependence on the validation of vector performance and the success of macular dystrophy therapy. The company attracts a team of top biologists through stock options and scientific freedom. Currently, the startup is scaling its ophthalmological and cardiological developments by implementing innovative treatment standards.

Defensive portfolio screening requires strict control of debt load to minimize default risks. This indicator is calculated as the sum of all liabilities divided by the company's equity. For 4D Molecular Therapeutics (FDMT), a low level of borrowing is critical, as the company finances its staff of elite biologists primarily through equity issuance. The total debt-to-equity ratio reflects the sustainability of this development model.